David Wainer

Moderna and Merck are surging today after the two companies said their experimental mRNA-based treatment succeeded i

Personalized mRNA shots may prove neither as wide-reaching nor as lucrative as hoped.

Moderna has always been a stock driven by narrative extremes. During the pandemic, it traded as if mRNA would transform medicine overnight, with its market capitalization peaking near $200 billion.

Plus, a defense-stock opportunity and timber cut down

Good morning, I'm filling in for Spencer Jakab. Markets are holding their breath until Kevin Warsh speaks at the Jackson Hole symposium later this morning.

Bourbon butterscotch creme brûlée at Butcher & Bull.

The chain’s affluent, older base gives it an edge. But to grow it also needs young customers.

Affluent older Americans might be the best customers in U.S. dining. They have savings, are relatively insulated from economic swings and, most valuable to a restaurant chain, prefer the familiar to the trendy.

Tempus AI could capture a lucrative slice of Moderna and Merck’s personalized cancer therapy business, with Personalis at the center of the bet.

The excitement surrounding Moderna and Merck's personalized mRNA cancer vaccine added more than $50 billion in combined market value for the two drug companies.